Alpha Cognition Obtains New U.S. Patent for ZUNVEYL in Alzheimer's Treatment

VANCOUVER—Alpha Cognition Inc., a biopharmaceutical entity listed on NASDAQ as ACOG, has recently secured a significant patent from the United States Patent and Trademark Office (USPTO). This new patent is titled "Coated Tablets for pH-Dependent Release of Benzgalantamine" and is a noteworthy addition to the company’s intellectual property assets. It provides exclusive rights related to the composition of benzgalantamine tablet formulations, thereby extending the company's existing patent repertoire. This protection remains effective in the United States until 2044, aligning with Alpha Cognition’s broader strategy aimed at sustained growth and impending market rollouts.

Michael McFadden, the CEO of Alpha Cognition, highlights the importance of this patent approval, emphasizing that it showcases the uniqueness of their product, ZUNVEYL. This development is timely, aligning with the company's scheduled launch of ZUNVEYL in the U.S. within the current quarter. The patent fortification places Alpha Cognition in a favorable position to exploit ZUNVEYL's full potential, continuing their mission to innovate solutions for Alzheimer’s disease sufferers.

ZUNVEYL is introduced as a pioneering treatment approach targeting symptoms of Alzheimer’s. It aims to enhance patient experiences by optimizing how the medication is delivered. Anticipation builds towards Q1 2025, when ZUNVEYL is expected to be available nationwide by prescription, marking a crucial phase in Alpha Cognition’s commercial journey.

Alpha Cognition Inc. is at the forefront of clinical-stage biopharmaceutical advancements, focusing on developing therapies for neurodegenerative conditions like Alzheimer’s and Cognitive Impairment linked with mild Traumatic Brain Injury (mTBI). Currently, there are no approved medical interventions for these disorders, placing the company in a pivotal role within the therapeutic landscape.

As Alpha Cognition looks towards the future, the recent patent not only supports their immediate commercial endeavors but also symbolizes a commitment to addressing significant unmet needs in neurodegenerative disease management. By securing this patent, Alpha Cognition fortifies its competitive position in the industry, ensuring that their innovative therapeutic solutions reach patients who need them most.